BioSpace News Archive

There is one person missing to complete the team

Recruiting

Facing Talent Crunch, Radiopharma Field Casts a Wide Net

As the field grows rapidly, companies are luring people from other nuclear industries and tapping the expanding educational talent pipeline, but are constrained by a steep learning curve and the value of real-world experience.

February 10, 2026

·

4 min read

·

Nick Paul Taylor

Her-2 - Test with blood sample. Top view isolated on office desk. Healthcare or Medical concept

Insights

HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs

As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low and ultra-low expressors, match patients to the right therapies and make more precise treatment decisions.

February 10, 2026

·

3 min read

·

Jennifer Smith-Parker

Focus on the path, Businessman running on his own track

Earnings

AstraZeneca Teases ‘Very Competitive’ Weight-Loss Pill—But Stays Mum on Details

AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a monotherapy, as part of a combination regimen and for several indications.

February 10, 2026

·

2 min read

·

Tristan Manalac

Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.

Obesity

Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study

Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.

February 10, 2026

·

1 min read

·

Tristan Manalac

Creative picture image collage banner of guy worker jump from financial charts determined company success.

Immunology and inflammation

Evommune Soars as Dermatitis Treatment Rivals Dupixent in Mid-Stage Trial

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical trial.

February 10, 2026

·

1 min read

·

Dan Samorodnitsky

Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.

Complete response letters

REGENXBIO’s Hunter Syndrome Gene Therapy Fails To Win FDA Nod

The FDA recommended that REGENXBIO run a new study, treat more patients and include a placebo arm to support a resubmission for the gene therapy RGX-121.

February 10, 2026

·

2 min read

·

Tristan Manalac

CAREER ADVICE

Webinar: 2026 Hiring Trends and Job Market Signals

This webinar provides a clear-eyed assessment of current hiring conditions across biopharma, exploring which roles and skills are in demand, where opportunities are emerging, and how hiring practices are evolving.

February 10, 2026

·

1 min read

·

BioSpace Insights

Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.

Regulatory

Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter

The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects, and other vermin.”

February 10, 2026

·

2 min read

·

Tristan Manalac

Press Releases

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

February 10, 2026

·

4 min read

Press Releases

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

February 10, 2026

·

5 min read